Clinical Trial Update: Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update for cediranib maleate in patients with recurrent or metastatic head and neck squamous cell carcinoma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Nasal Cavity and Paranasal Sinus Cancer
• Nasopharyngeal Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Salivary Gland Cancer

Drugs mentioned

• Cediranib Maleate (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED